N/A N=69 Assessment of Two Postoperative Techniques Used to Predict Voiding Efficiency After Gynecologic Surgery
Urinary Incontinence
Primary: Number of Participants Who Passed Bladder Trial — 25; 39 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial
Major Depressive Disorder · Alcohol Use Disorder
Primary: Drinks Per Drinking Day — 2.8; 2.0 Drinks per drinking day
Phase 2 N=35 Itch Relieving Effect of Botox: a Study in Healthy Subjects
Pruritus
Primary: Itch by VAS Itch Intensity at Baseline (Visit 1) — 4.5; 4.3; 6.5; 6.3 units on a scale — p=0.9704
N/A N=2,116 Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children
Dengue
Primary: Incidence of All Laboratory-confirmed Symptomatic Dengue Infection — 10.5; 11.5 Cases in 1000 person-years
Phase 1 N=16 Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects
Healthy Volunteers
Primary: Symptoms of Dry Mouth — 3; 1; 3; 1 Participants
N/A N=964 Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event
Congestive Heart Failure
Primary: Numerical Heart to Mediastinum (H/M) Ratio at 3 Hours 50 Minutes Post-administration on Planar 123I-mIBG Imaging by Adverse Cardiac Events (ACEs) Status — 1.451; 1.394…
Phase 2 N=15 Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
Endometrial Carcinoma
Primary: Number of Participants With Progression Free Survival (PFS=Date of Progression of Disease or Death) at 6 Months Using Bevacizumab, Carboplatin, and Paclitaxel in…
Phase 3 N=666 A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
Breast Neoplasms
Primary: Progression-Free Survival (PFS) as Assessed by the Investigator — 24.8; 14.5 Months — p=<0.000001
Phase 4 N=407 NAVISTAR® THERMOCOOL® Catheter Post Approval Registry
Paroxysmal Atrial Fibrillation
Primary: The Percentage of Subjects Experiencing Primary Adverse Events Within Seven Days of the Ablation Procedure. — 3.2; 6.4 percentage of participants
Phase 1 N=49 Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs
Crohn's Disease · Ileitis · Ileo-colonic and Colonic Crohn's Disease
Primary: Cohort 2: Baseline Absolute Lymphocyte Count in Cerebrospinal Fluid (CSF) — 338.5 cells per milliliter (cells/mL)
Phase 2 N=23 Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma · Lymphoma, Diffuse Large-Cell · Diffuse Large-Cell Lymphoma
Primary: Complete Response (CR) Rate as Defined by The International Harmonization Project for Response Criteria — 52 percentage of participants
N/A N=982 Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration -
Pneumonia · Lung Abscess · Peritonitis
Primary: Number of Participants With Treatment-Related Adverse Events — 96 Participants
N/A N=251 Efficacy of Post-operative Antibiotic Prophylaxis for Thoracic Surgery Requiring Tube Thoracostomy
Antibiotic Prophylaxis
Primary: Number of Participants Who Experienced At Least One Postoperative Infectious Complication — 13; 8 Participants — p=.26
Phase 4 N=17 Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses
Actinic Keratoses
Primary: Safety of Combination Therapy vs Cryotherapy Alone — 0; 0 Participants
Phase 1 N=95 PK Study of PT003 and PT001 in Japanese Healthy Subjects
COPD
Primary: Cmax — 15.23; 9.09; 16.85; 7.26 pg/mL